<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983108</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-ACLF-07</org_study_id>
    <nct_id>NCT04983108</nct_id>
  </id_info>
  <brief_title>Utility of Liver and Splenic Stiffness in Predicting Esophageal Varices in Patients With Acute on Chronic Liver Failure</brief_title>
  <official_title>Utility of Liver and Splenic Stiffness in Predicting Esophageal Varices in Patients With Acute on Chronic Liver Failure- A Cross-Sectional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monitoring and Assessment: Transient Elastography will be performed in morning hours using&#xD;
      the FibroScan apparatus (Echosens), which consists of a 5-MHz ultrasound transducer probe&#xD;
      mounted on the axis of a vibrator. The tip of the transducer (M-or XL probe) will be covered&#xD;
      with a drop of gel and placed perpendicularly in the intercostal space, with the patient&#xD;
      lying in dorsal decubitus position with the right arm in the maximal abduction. Under&#xD;
      control, in time motion and in A-mode, the operator will choose a liver portion within the&#xD;
      right liver lobe, at least 6-cm thick and free of large vascular structures, and the&#xD;
      gallbladder. Liver stiffness (LS) will be measured on a cylinder of hepatic tissue of 1 cm of&#xD;
      diameter and 4 cm of length. For assessing the splenic stiffness (SS), the patient will be in&#xD;
      supine position with left arm in maximum abduction. Ultrasonography will be used to identify&#xD;
      and locate the spleen parenchyma, to choose the right place for SS measurement, and to&#xD;
      measure the spleen diameter (long axis). Transducer will be placed in the left intercostal&#xD;
      spaces, with location indicated by the ultrasound. A median value of 10 successful&#xD;
      acquisitions, expressed in kPa, will be kept as a representative of the LS and SS&#xD;
      measurements. The LS and SS measurement failure will be recorded when no value will be&#xD;
      obtained after at least 10 shots. The results will be considered unreliable in the following&#xD;
      circumstances: valid shots fewer than 10, success rate &lt; 60%, or interquartile range / LS &gt;30&#xD;
      %. Liver and splenic stiffness, LSPS score (LS measurement Ã— spleen diameter / platelet&#xD;
      count), Platelet count to spleen diameter ratio (PSR) will be calculated. Patient will also&#xD;
      undergo upper g.i. endoscopy on same day. HVPG and TJLB will be done if indicated. The study&#xD;
      will assess whether the stiffness scores correlate with presence of esophageal varices.&#xD;
      Optimum cutoffs will be calculated for predicting the presence of esophageal varices.&#xD;
&#xD;
        -  Study design: A Cross-Sectional Study&#xD;
&#xD;
        -  Study period: 12 months&#xD;
&#xD;
        -  Sample size with justification: Consecutive Patients of ACLF from approval of study to&#xD;
           12 months. ACLF patients will be screened and eligible patients will be taken in to the&#xD;
           study.&#xD;
&#xD;
        -  Intervention: Patients of ACLF will undergo upper g.i. endoscopy, liver and splenic&#xD;
           stiffness measurement. HVPG and TJLB will be done in the patients only if clinically&#xD;
           indicated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the utility of liver and splenic stiffness to predict presence of esophageal varices in patients of ACLF.</measure>
    <time_frame>Day 1</time_frame>
    <description>Utility will be find out from the cut off values of ROC with maximum sensitivity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study the correlation of liver and splenic stiffness with grade of Esophageal varices.</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study utility of liver and splenic stiffness in evaluating Esophageal varices in comparison with other non-invasive tests.</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Develop a model utilizing non-invasive tests for prediction of EV in ACLF.</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study correlation of liver and splenic stiffness with HVPG in patients of ACLF.</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound parameters predicting failure of splenic stiffness in patients of ACLF.</measure>
    <time_frame>Day 1</time_frame>
    <description>Ultrasound parameters such as spleen size, degree of ascites would be assessed for failure of splenic stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters predicting failure of splenic stiffness in patients of ACLF.</measure>
    <time_frame>Day 1</time_frame>
    <description>Clinical parameters such as BMI would be assessed for failure of splenic stiffness.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No intervention. This is an observational Study</description>
    <other_name>This is an observational Study</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients of ACLF fulfilling the APASL (Asian Pacific Association for the Study&#xD;
        of the Liver) criteria undergoing HVPG and TJLB and upper gastrointestinal endoscopy for&#xD;
        variceal screening.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients of ACLF (APASL criteria).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 and &gt; 70 years&#xD;
&#xD;
          2. moderate to severe ascites&#xD;
&#xD;
          3. Portal Vein Thrombosis&#xD;
&#xD;
          4. Hepatocellular carcinoma&#xD;
&#xD;
          5. space occupying lesion liver&#xD;
&#xD;
          6. heart failure&#xD;
&#xD;
          7. biliary obstruction&#xD;
&#xD;
          8. prior variceal endotherapy or ongoing beta blocker treatment for varices&#xD;
&#xD;
          9. pregnancy&#xD;
&#xD;
         10. ICD / pacemaker&#xD;
&#xD;
         11. ongoing treatment for HBV&#xD;
&#xD;
         12. HCV or ended within 3 months&#xD;
&#xD;
         13. No consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Chitranshu Vashishtha, DM</last_name>
    <phone>01146300000</phone>
    <email>chitranshuv@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Chitranshu Vashishtha, DM</last_name>
      <phone>01146300000</phone>
      <email>chitranshuv@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

